Results 121 to 130 of about 6,309 (194)

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J, Stockerl-Goldstein, Keith E, Zhang, Kathleen W   +2 more
core   +1 more source

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary. [PDF]

Future Cardiol
Wixner J, Dispenzieri A, Amass L, Carlsson M, Riley S, Powers E, Kelly JW.   +6 more
europepmc   +1 more source

Technetium-99m-labeled pyrophosphate uptake in the rectum of a patient with wild-type transthyretin cardiac amyloidosis. [PDF]

Radiol Case Rep
Takahashi K, Sasaki D, Yamamoto S, Yamamura N, Utsunomiya Y, Morioka H, Uemura S, Sakaue T, Inoue K.   +8 more
europepmc   +1 more source

Tafamidis Beyond the ATTR-ACT Trial

JACC: Advances, 2022
René Rettl, Diana Bonderman
openaire   +1 more source

Phenomenological model of transthyretin stabilization. [PDF]

Sci Rep
Lisowski B, Ulaszek S, Wiśniowska B, Bernhauerová V, Polak S.   +4 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: from cause to novel treatments. [PDF]

Eur Heart J
Fontana M, Aimo A, Emdin M, Porcari A, Solomon SD, Hawkins PN, Gillmore JD.   +6 more
europepmc   +1 more source

Global Longitudinal Strain for Prognostic Staging in Wild-Type Transthyretin Cardiac Amyloidosis. [PDF]

Circ Cardiovasc Imaging
Debonnaire P, L'Hoyes W, Donal E, Verheyen N, Vervloet D, Dujardin K, Pouleur AC, Dulgheru R, Sarli Issa V, Droogmans S, Jurcut R, Regeer M, Dupont M, Bondue A, Timmermans P, Bohyn A, Christiaen E, Wyseure N, Bezard M, Zach D, Schwegel N, Knapen R, Buytaert L, de Marneffe N, Adam R, Ajmone Marsan N, Tavernier R, Buysschaert I, Trenson S.   +28 more
europepmc   +1 more source

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis. [PDF]

Eur Heart J Open
Aimo A, Castiglione V, Emdin M, Lorenzoni V, Vergaro G.   +4 more
europepmc   +1 more source

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study [PDF]

core   +1 more source

Discontinuation of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients. [PDF]

Circ Rep
Baba Y, Ochi Y, Kubo T, Kawaguchi J, Yamasaki N, Kitaoka H.   +5 more
europepmc   +1 more source